However, when self-assembled as 12 nm nanoparticles (above the renal filtration cut-off) and actively targeted to CXCR4+ cells with T22, it shows absence of renal clearance and outstanding tumor specificity with most of the administered material accumulated in target tissue in different models of solid tumors and hematological malignances [32,34,42]. The gene discussed is CXCR4; the disease is cancer.